The relationship between hyperpolypharmacy and one-year outcomes in patients with critical limb ischemia undergoing below-knee endovascular therapy.
Mehmet AltunovaRecep GulmezMuammer KarakayalıIsmail GurbakOmer TasbulakGökhan DemirciArda GulerAli EvsenUmit BulutMehmet ErturkPublished in: Vascular (2023)
Hyperpolypharmacy was significantly associated with 1-year mortality and major amputation in CLI patients. Hyperpolypharmacy can be a valuable aid in patient risk assessment in the CLI.
Keyphrases
- risk assessment
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- case report
- cardiovascular events
- stem cells
- risk factors
- type diabetes
- cardiovascular disease
- patient reported outcomes
- metabolic syndrome
- skeletal muscle
- insulin resistance
- peripheral artery disease
- glycemic control
- chemotherapy induced